Physicians should expect tough patient questions about niacin

03/15/2013 | MedPage Today (free registration)

Patients are asking about niacin therapy in light of results from the HPS2-THRIVE study, which failed to substantiate hopes that extended-release niacin/laropiprant would reduce major vascular events. "The average patient might think, upon reading results of the THRIVE study, that the risks of niacin clearly outweigh the benefits when it comes to preventing heart disease. It's our job to explain that it's not that simple," writes Dr. Sanjay Gupta.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID